| 2026年中报 | 2025年年报 | 2025年中报 | 2025年一季报 | 2024年年报 | 2024年三季报 | |
|---|---|---|---|---|---|---|
| 营业收入(元) | ||||||
| CMO业务(元) | 13,465,102.53 | 36,773,874.76 | 22,031,815.26 | 10,187,352.12 | 33,129,316.10 | 24,699,912.82 |
| CRO业务(元) | - | - | - | - | - | 320,399,133.30 |
| 原料药业务(元) | 28,080,981.11 | 53,567,422.80 | 22,820,328.76 | 9,949,227.20 | 53,741,259.84 | 38,773,585.64 |
| CRO业务-受托研发服务(元) | 17,813,634.08 | 58,446,402.21 | 37,544,155.66 | 9,562,197.21 | 93,008,247.72 | - |
| CRO业务-研发成果转化(元) | 149,734,629.04 | 369,173,103.05 | 202,933,362.75 | 100,856,916.57 | 390,545,601.55 | - |
| 其他(元) | 3,690,813.04 | 2,418,248.54 | 1,499,489.90 | 1,109,917.12 | 8,030,482.70 | 7,692,129.32 |
| 营业成本(元) | ||||||
| CMO业务(元) | 9,916,713.13 | 19,220,911.87 | 10,259,232.89 | 4,847,531.19 | 19,417,359.81 | 13,979,023.18 |
| CRO业务(元) | - | - | - | - | - | 55,646,104.50 |
| 原料药业务(元) | 18,948,885.74 | 36,302,491.70 | 13,837,814.15 | 6,084,264.90 | 31,340,741.91 | 21,176,156.09 |
| CRO业务-受托研发服务(元) | 3,901,750.28 | 19,975,127.22 | 9,315,408.62 | 2,468,469.18 | 27,289,027.69 | - |
| CRO业务-研发成果转化(元) | 32,104,602.99 | 66,883,831.45 | 33,770,979.13 | 19,827,439.50 | 63,086,837.92 | - |
| 其他(元) | 2,514,312.49 | 1,079,940.28 | 864,409.29 | 932,618.77 | 209,715.60 | 297,420.55 |
| 毛利(元) | ||||||
| CMO业务(元) | 3,548,389.40 | 17,552,962.89 | 11,772,582.37 | 5,339,820.93 | 13,711,956.29 | 10,720,889.64 |
| CRO业务(元) | - | - | - | - | - | 264,753,028.80 |
| 原料药业务(元) | 9,132,095.37 | 17,264,931.10 | 8,982,514.61 | 3,864,962.30 | 22,400,517.93 | 17,597,429.55 |
| CRO业务-受托研发服务(元) | 13,911,883.80 | 38,471,274.99 | 28,228,747.04 | 7,093,728.03 | 65,719,220.03 | - |
| CRO业务-研发成果转化(元) | 117,630,026.05 | 302,289,271.60 | 169,162,383.62 | 81,029,477.07 | 327,458,763.63 | - |
| 其他(元) | 1,176,500.55 | 1,338,308.26 | 635,080.61 | 177,298.35 | 7,820,767.10 | 7,394,708.77 |
| 毛利率(%) | ||||||
| CMO业务(%) | 26.35 | 47.73 | 53.43 | 52.42 | 41.39 | 43.40 |
| CRO业务(%) | - | - | - | - | - | 82.63 |
| 原料药业务(%) | 32.52 | 32.23 | 39.36 | 38.85 | 41.68 | 45.39 |
| CRO业务-受托研发服务(%) | 78.10 | 65.82 | 75.19 | 74.19 | 70.66 | - |
| CRO业务-研发成果转化(%) | 78.56 | 81.88 | 83.36 | 80.34 | 83.85 | - |
| 其他(%) | 31.88 | 55.34 | 42.35 | 15.97 | 97.39 | 96.13 |
| 收入构成(%) | ||||||
| CMO业务(%) | 6.33 | 7.07 | 7.68 | 7.74 | 5.73 | 6.31 |
| CRO业务(%) | - | - | - | - | - | 81.83 |
| 原料药业务(%) | 13.20 | 10.29 | 7.96 | 7.56 | 9.29 | 9.90 |
| CRO业务-受托研发服务(%) | 8.37 | 11.23 | 13.09 | 7.26 | 16.08 | - |
| CRO业务-研发成果转化(%) | 70.37 | 70.94 | 70.75 | 76.60 | 67.52 | - |
| 其他(%) | 1.73 | 0.46 | 0.52 | 0.84 | 1.39 | 1.96 |
| 毛利构成(%) | ||||||
| CMO业务(%) | 2.44 | 4.66 | 5.38 | 5.48 | 3.14 | 3.57 |
| CRO业务(%) | - | - | - | - | - | 88.11 |
| 原料药业务(%) | 6.28 | 4.58 | 4.11 | 3.96 | 5.12 | 5.86 |
| CRO业务-受托研发服务(%) | 9.57 | 10.21 | 12.90 | 7.28 | 15.03 | - |
| CRO业务-研发成果转化(%) | 80.90 | 80.20 | 77.32 | 83.10 | 74.91 | - |
| 其他(%) | 0.81 | 0.36 | 0.29 | 0.18 | 1.79 | 2.46 |